Company Operations by Product, Customer and Geographic Area

The Company has determined that we operate in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2018, 2017, and 2016:



Revenue by Product:	2018		2017		2016

Bloxiverz	$	20,850	$	45,596	$	82,896
Vazculep	42,916		38,187		39,796
Akovaz	33,759		80,617		16,831
Noctiva	1,204		—		—
Other	2,694		8,441		7,699
Total product sales	101,423		172,841		147,222
License revenue	1,846		404		3,024
Total revenues	$	103,269	$	173,245	$	150,246

Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of our customers and believes that we have adequately provided for any exposure to potential credit loss.

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2018, 2017, and 2016:



Revenue by Significant Customer:	2018		2017		2016

Customer A	$	26,794	$	44,762	$	51,648
Customer B	25,413		37,965		39,359
Customer C	18,620		25,691		30,916
Customer D	9,653		53,342		17,728
Others	20,943		11,081		7,571
Total product sales	101,423		172,841		147,222
License revenue	1,846		404		3,024
Total revenues	$	103,269	$	173,245	$	150,246

As of December 31, 2018, the Company had four customers, each of which are substantial wholesale distributors, and accounted for 10% or more of the accounts receivable balance. One customer accounted for 32%, or $3,571, a second customer accounted for 24% or $2,755, a third customer accounted for 24% or $2,789, and a fourth customer accounted for 10% or $1,174. As of December 31, 2018, the Company had no significant past due account receivable balances.

The following table summarizes revenues by geographic region for the twelve months ended December 31, 2018, 2017, and 2016:



Revenue by Geographic Region:	2018		2017		2016

United States	$	101,423	$	172,841	$	147,283
Ireland	1,846		404		2,963
Total revenues	$	103,269	$	173,245	$	150,246

Currently we depend on a single contract manufacturing organization for the manufacture of Bloxiverz, Vazculep and Noctiva and two contract manufacturing organizations for the manufacture of Akovaz, from which we derive a majority of our revenues. Additionally, we purchase certain raw materials used in our products from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2018, 2017, and 2016:



Long-lived Assets by Geographic Region:	2018		2017		2016

United States	$	27,761	$	116,536	$	42,021
France	1,365		2,257		2,524
Ireland	6,028		1,360		202
Total	$	35,154	$	120,153	$	44,747